Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Dye

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
JMIR Research Protocols|March 8, 2017
Enhancing mHealth Technology in the Patient-Centered Medical Home Environment to Activate Patients With Type 2 Diabetes: A Multisite Feasibility Study ProtocolRonald Gimbel, Lu Shi, Joel E Williams, et al.
HGG Advances|July 20, 2024
Clinical and functional studies of MTOR variants in Smith-Kingsmore syndrome reveal deficits of circadian rhythm and sleep-wake behaviorAndrew C Liu, Yang Shen, Carolyn R Serbinski, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 24, 2019
Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPTJennifer Velloza, Peter Bacchetti, Craig W Hendrix, et al.
The Lancet. HIV|October 8, 2017
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trialLinda-Gail Bekker, Surita Roux, Elaine Sebastien, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 8, 2015
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058David S Metzger, Deborah Donnell, David D Celentano, et al.
Plos Medicine|June 18, 2021
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trialConnie Celum, Sybil Hosek, Mandisa Tsholwana, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 9, 2018
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT StudyRobert M Grant, Sharon Mannheimer, James P Hughes, et al.
Micropublication Biology|March 23, 2026
Bay leaf extract is a chemotaxis repellent for <i>C. elegans</i>Samuel H Wu, Anna Amine, Kaya Ben-Efraim, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Micropublication Biology|March 27, 2026
Four Neotropical frog species exhibit shared and distinct skin bacterial communities in a laboratory settingViraj Jansari, Daniela A Castro-Martinez, Melody J Dailey, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
JMIR Research Protocols|March 8, 2017
Enhancing mHealth Technology in the Patient-Centered Medical Home Environment to Activate Patients With Type 2 Diabetes: A Multisite Feasibility Study ProtocolRonald Gimbel, Lu Shi, Joel E Williams, et al.
HGG Advances|July 20, 2024
Clinical and functional studies of MTOR variants in Smith-Kingsmore syndrome reveal deficits of circadian rhythm and sleep-wake behaviorAndrew C Liu, Yang Shen, Carolyn R Serbinski, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 24, 2019
Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPTJennifer Velloza, Peter Bacchetti, Craig W Hendrix, et al.
The Lancet. HIV|October 8, 2017
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trialLinda-Gail Bekker, Surita Roux, Elaine Sebastien, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 8, 2015
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058David S Metzger, Deborah Donnell, David D Celentano, et al.
Plos Medicine|June 18, 2021
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trialConnie Celum, Sybil Hosek, Mandisa Tsholwana, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 9, 2018
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT StudyRobert M Grant, Sharon Mannheimer, James P Hughes, et al.
Micropublication Biology|March 23, 2026
Bay leaf extract is a chemotaxis repellent for <i>C. elegans</i>Samuel H Wu, Anna Amine, Kaya Ben-Efraim, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Micropublication Biology|March 27, 2026
Four Neotropical frog species exhibit shared and distinct skin bacterial communities in a laboratory settingViraj Jansari, Daniela A Castro-Martinez, Melody J Dailey, et al.
Pageof 14